Jason B. Daly - 03 Mar 2022 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMRX	Restricted Stock Units	Award	$0	+90,580		$0.000000	90,580	03 Mar 2022	Class A Common Stock	90,580		Direct	F1, F2
transaction	AMRX	Performance-Based Restricted Stock Units	Award	$0	+181,160		$0.000000	181,160	03 Mar 2022	Class A Common Stock	181,160		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2	The restricted stock units vest in four equal annual installments beginning on March 3, 2023.
F3	Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F4	Represents a performance-based restricted stock unit grant of 90,580 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period.